source
- AbbVie reports 60% reduction in progression risk for myeloma drug etentamig in Phase 3 trialAbbVie announced results from a Phase 3 study of its T cell engager etentamig in patients with multiple myeloma. The trial demonstrated a 60% relative reduction in the risk of disease progression…
- B. Braun recalls three lots of 0.9% Sodium Chloride injection due to zinc oxide particlesB. Braun Medical Inc announced a voluntary recall of three lots of its 0.9% Sodium Chloride Injection USP, 100 mL, packaged in a 150 mL PAB® container. The recall was triggered after testing ident…